Peptonic Medical AB (publ) (“Peptonic”) is taking a crucial step to establish its VagiVital brand in the U.S. market and drive sales growth of its
Peptonic Medical (publ) today announced that Apotek Hjärtat is initiating sales of the company’s leading intimate care product VagiVital® AktivGel in most of its physical
Peptonic Medical (publ) today informed the company has signed an exclusive distributor agreement for Central Amerika with Windsor Pharmaceutical concerning the companys vaginal self tests
Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the company has entered into an agreement with fermata Inc. for the Japan market. The agreement
Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces today that it has decided to exercise the right to convert the loan of SEK 7.5
www.aktietorget.se ticker: PMED 2019 third quarter (Jul-Sep) Net sales of products KSEK 1,557 (120) Gross profit KSEK 692 (95), Gross margin 45% (79%) Operating loss
2019 first quarter (Apr-Jun) Net sales of products KSEK 1,011 (0) Gross profit KSEK 768 (0), Gross margin 76% (0%) Operating loss KSEK -5,102 (-3,563)
The Board of Directors of Peptonic Medical AB (publ) (Peptonic or Company) today announced the decision to commence the process of obtaining CE-marking for the
Peptonic Medical AB (publ) today announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel
Peptonic Medical AB (publ) (“the Company” or “Peptonic”) – a company developing pharmaceuticals based on oxytocin – today announced that 57 study subjects have been
PEPTONIC medical (publ) today announced it has engaged five study sites, all of them in Sweden, to participate in the next Phase 2b study and
PEPTONIC medical today announced the tentative program for company presentations during the subscription period for the rights issue in connection with the planned listing (IPO)
PEPTONIC medical today announces that, at the PEPTONIC medical Annual General Meeting on April 8th, Mrs Nadia Whittley was elected as a new member to
PEPTONIC medical (publ) today announced that the Annual General Meeting (AGM) on April 8th resolved to make the Company to a public company. In conjunction
PEPTONIC medical today announced that it has recruited Johan Inborr to lead the business development activities of the company on a consultancy basis. Johan is
PEPTONIC medical today announced that it has raised SEK 6.9 million in a directed private placement to existing and new shareholders. After the private placement,
PEPTONIC medical today announced that it has completed the evaluation of different tube models and materials for use as primary packaging of VAGITOCIN® – the
PEPTONIC medical today announced that the last patient participating in the VAGITOCIN® pharmacokinetic (PK) study has been discharged after a final visit to the physician
PEPTONIC medical today announced that it met with the US Food and Drug Administration (FDA) earlier this month in a so called pre-IND meeting. The
PEPONIC medical has signed an agreement with Destum Partners in USA for support in finding suitable collaboration partners. By using a US based consulting company
PEPTONIC has started a collaboration with Clinartis in USA. Clinartis is a consulting company within the clinical/regulatory area. They support us in the work with
A regulatory/scientific, advisory meeting has been performed at the MPA on the 25.3.13. The results from the recently concluded clinical study and the design of
A new formulation patent for oxytocin was approved by the Swedish patent authorities in February 2013. PEPTONIC has received a patent on the new formulation
PEPTONIC medical has concluded a preference share emission which gave 13,6 MSEK. During October 2012 a preference share emission was finished giving 13,6 MSEK. This
